Navigating risk, treatment and reimbursement in precision oncology

Providers can leverage predictive genomics not only to assess a person’s risk of developing cancer, but also to guide treatment decisions when cancer develops.  

Dr. Sadie Dobrozsi, Evolent’s medical director for genetic testing and oncology, joined the Managed Care Cast to discuss the state of predictive genomics, which goes beyond genetic testing to consider family history, environment, and a person’s overall health. In addition to explaining the uses of predictive genomics in prevention and treatment planning, Dr. Dobrozsi describes the landscape around reimbursement for tests in a rapidly changing environment.

Topics covered in this episode:

• 1:32 – What is predictive genomics?
• 2:50 – How predictive genomics informs risk reduction.
• 7:38 – The landscape around reimbursement for genetic testing for germline mutations.
• 10:00 – How predictive genomics supports treatment selection.
• 14:25 – How the biology of a cancer can help predict whether a specific chemotherapy will benefit a patient.
• 16:40 – The use of pharmacogenomics to improve treatment selection and tailor dosing.  
• 21:18 – The challenge that clinicians face keeping up with rapid change and innovation in the field of predictive genomics.
• 25:14 – Reimbursement for genetic tests that are used to inform treatment.
• 26:57 – The importance for genetic tests to lead to treatment changes, which in tun result in better outcomes.
• 29:49 – How Evolent helps inform selection of genetic tests.

Listen to the podcast.